Name	Motoko Yamaguchi, MD, PhD
Current Position & Affiliation	Professor, Department of Hematological Malignancies, Mie University Graduate School of Medicine
Country	Japan
Major Field	Hematology

Educational Background

Ph.D., Graduate School of Medicine, Mie University, 1997
M.D., Faculty of Medicine, Mie University, 1989

Professional Experience

- Professor, Department of Hematological Malignancies, Mie University Graduate School of Medicine, 2021 - Present
- Associate Professor, Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2020 - 2021
- Assistant Professor, Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2002 -2020
- Medical Staff, Second Department of Internal Medicine, Mie University School of Medicine, 1993 -2002; Internal Medicine, National Myojyo Hospital, 1991-1993
- Resident, Internal Medicine, Ise Municipal General Hospital, 1990-1991; Second Department of Internal Medicine, Mie University Hospital, 1989

Other Experience and Professional Memberships

- Executive director, Japanese Society of Hematology (JSH)
- Executive director, Japanese Society of Lymphoma Research (JSLR)
- Councilor, Japanese Cancer Association (JCA); Member, JSMO, JSCO, ASH, ASCO
- Member of Executive Committee, Chair of the Data and Safety Monitoring Committee, the Japan Clinical Oncology Group (JCOG)
- Clinical Advisory Committee for Lymphoid Neoplasms of the 2008 WHO classification
- Co-author of the 2022 WHO Classification (ENKL, ANKL)

Main Scientific Publications

1. Yamaguchi M, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol 35: 32-9, 2017
2. Yamaguchi M, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29: 4410-6, 2011
3. Yamaguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27: 5594–600, 2009
4. Yamaguchi M, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell

lymphoma cells. Cancer 76: 2351-6, 1995